This site is intended for healthcare professionals

European Commission approves Lynparza + Avastin as first line maintenance treatment of ovarian cancer.- AstraZeneca + Merck Inc.

Read time: 1 mins
Last updated:11th Nov 2020
Published:11th Nov 2020
Condition: Ovarian Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest